Skip to main content
SpringerLink
Log in

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Advances in the management of multiple myeloma (MM) have led to a significant prolongation of both progression-free (PFS) and overall survival (OS). Herein, we evaluated the characteristics of patients who achieved a PFS of at least 7 years following frontline therapy, as compared with all other patients who were treated in a single center during the same time period. Thirty-six (8.8%) patients achieved a PFS of at least 7 years (long PFS group) after frontline treatment. Long PFS patients were younger (p < 0.001) and had lower ECOG performance status (p = 0.014), higher hemoglobin (p = 0.001), and higher creatinine clearance (p < 0.001) compared with the others. More patients in the long PFS group had ISS-1 or ISS-2 disease (p = 0.002) and normal pattern of marrow infiltration (p = 0.035). No patient in the long PFS group had high-risk cytogenetics at diagnosis. Long PFS patients had received more often autologous stem cell transplantation (p = 0.001) and had achieved deeper responses. The probability of achieving long PFS (≥ 7 years) for patients who managed to be progression-free at 2, 3, and 4 years was 11.6%, 13.2%, and 15.3%, respectively. Median OS in the long PFS group has not been reached yet, while in all other patients, the median OS was 4.3 years. In conclusion, our study in an unselected patient group showed that 9% of patients with newly diagnosed myeloma experience prolonged PFS of more than 7 years in the era of conventional chemotherapy or first-generation novel agents. We anticipate that novel treatment approaches will increase the probability of achieving a prolonged relapse-free status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC (2017) Multiple myeloma. Nat Rev Dis Primers 3:17046. https://doi.org/10.1038/nrdp.2017.46

    Article  PubMed  Google Scholar 

  2. Castaneda-Avila MA, Ortiz-Ortiz KJ, Torres-Cintron CR, Birmann BM, Epstein MM (2019) Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013. Int J Cancer 146:35–43. https://doi.org/10.1002/ijc.32232

    Article  PubMed  CAS  Google Scholar 

  3. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J (2014) Curing myeloma at last: defining criteria and providing the evidence. Blood 124(20):3043–3051. https://doi.org/10.1182/blood-2014-07-552059

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Verelst SGR, Blommestein HM, De Groot S, Gonzalez-McQuire S, DeCosta L, de Raad JB, Uyl-de Groot CA, Sonneveld P (2018) Long-term outcomes in patients with multiple myeloma. A retrospective analysis of the Dutch population-based HAematological registry for observational studies (PHAROS). HemaSphere 2(4):e45. https://doi.org/10.1097/HS9.0000000000000045

    Article  PubMed  PubMed Central  Google Scholar 

  5. Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D (2016) Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol 9(7):707–717. https://doi.org/10.1080/17474086.2016.1195254

    Article  PubMed  CAS  Google Scholar 

  6. Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, Rajkumar SV (2018) Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 8(3):26. https://doi.org/10.1038/s41408-018-0065-8

    Article  PubMed  PubMed Central  Google Scholar 

  7. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420. https://doi.org/10.1200/JCO.2005.04.242

    Article  PubMed  Google Scholar 

  8. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863–2869. https://doi.org/10.1200/JCO.2015.61.2267

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ, Group NHOS (2012) A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC myeloma IX trial. Leukemia 26(2):349–355. https://doi.org/10.1038/leu.2011.204

    Article  PubMed  CAS  Google Scholar 

  10. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G (2019) A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 33(1):159–170. https://doi.org/10.1038/s41375-018-0196-8

    Article  PubMed  CAS  Google Scholar 

  11. Pawlyn C, Davies FE (2019) Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 133(7):660–675. https://doi.org/10.1182/blood-2018-09-825331

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ (2018) Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132(6):587–597. https://doi.org/10.1182/blood-2018-03-840132

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Pawlyn C, Morgan GJ (2017) Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 17(9):543–556. https://doi.org/10.1038/nrc.2017.63

    Article  PubMed  CAS  Google Scholar 

  14. Lee SY, Kim HJ, Shin YR, Park HJ, Lee YG, Oh SJ (2017) Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis. Eur Radiol 27(6):2333–2347. https://doi.org/10.1007/s00330-016-4543-8

    Article  PubMed  Google Scholar 

  15. Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132(1):59–66. https://doi.org/10.1182/blood-2018-04-842880

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E (2015) Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 33(6):657–664. https://doi.org/10.1200/JCO.2014.57.9961

    Article  PubMed  Google Scholar 

  17. Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E (2014) Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25(1):195–200. https://doi.org/10.1093/annonc/mdt483

    Article  PubMed  CAS  Google Scholar 

  18. Dimopoulos MA, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas DC, Migkou M, Panagiotidis I, Eleutherakis-Papaiakovou E, Kanellias N, Psimenou E, Marinaki S, Bacharaki D, Mparmparoussi D, Matsouka C, Giannouli S, Terpos E, Kastritis E (2017) Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J 7(6):e571. https://doi.org/10.1038/bcj.2017.49

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E (2016) International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544–1557. https://doi.org/10.1200/JCO.2015.65.0044

    Article  PubMed  Google Scholar 

  20. Larocca A, Dold SM, Zweegman S, Terpos E, Wasch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M (2018) Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia 32(8):1697–1712. https://doi.org/10.1038/s41375-018-0142-9

    Article  PubMed  Google Scholar 

  21. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2):91–97. https://doi.org/10.1056/NEJM199607113350204

    Article  PubMed  CAS  Google Scholar 

  22. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working P (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875–1883. https://doi.org/10.1056/NEJMoa022340

    Article  PubMed  CAS  Google Scholar 

  23. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24(6):929–936. https://doi.org/10.1200/JCO.2005.04.5807

    Article  PubMed  CAS  Google Scholar 

  24. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J, Mateos MV, Palomera L, Fernandez-Calvo J, Marti JM, Giraldo P, Carbonell F, Callis M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J, Programa para el Estudio de la Terapeutica en Hemopatia M (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106(12):3755–3759. https://doi.org/10.1182/blood-2005-03-1301

    Article  PubMed  CAS  Google Scholar 

  25. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, Group M-A (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23(36):9227–9233. https://doi.org/10.1200/JCO.2005.03.0551

    Article  PubMed  CAS  Google Scholar 

  26. Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA (2020) Multiple myeloma: role of autologous transplantation. Cancer Treat Rev 82:101929. https://doi.org/10.1016/j.ctrv.2019.101929

    Article  PubMed  CAS  Google Scholar 

  27. Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, Gika D, Fotiou D, Kanellias N, Ziogas D, Ntanasis-Stathopoulos I, Barbarousi D, Gatou A, Katopi D, Manios E, Liontos M, Giannouli S, Tsirigotis P, Terpos E, Dimopoulos MA (2019) Early relapse post autologous transplant is associated with very poor survival and identifies an ultra high risk group of myeloma patients. Clin Lymphoma Myeloma Leuk [in press]

  28. Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A (2018) Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 32(4):986–995. https://doi.org/10.1038/leu.2017.331

    Article  PubMed  CAS  Google Scholar 

  29. Barlogie B (1991) Toward a cure for multiple myeloma? N Engl J Med 325(18):1304–1306. https://doi.org/10.1056/NEJM199110313251809

    Article  PubMed  CAS  Google Scholar 

  30. Martino M, Postorino M, Gallo GA, Messina G, Neri S, Piro E, Gentile M, Moscato T, Monteleone R, Fedele R, Mazzone C, Console G, Penna G, Alati C, Vincelli ID, Irrera G, Musolino C, Ronco F, Molica S, Morabito F (2014) Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Clin Lymphoma Myeloma Leuk 14(2):148–154. https://doi.org/10.1016/j.clml.2013.11.009

    Article  PubMed  Google Scholar 

  31. Fassas A, Shaughnessy J, Barlogie B (2005) Cure of myeloma: hype or reality? Bone Marrow Transplant 35(3):215–224. https://doi.org/10.1038/sj.bmt.1704757

    Article  PubMed  CAS  Google Scholar 

  32. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, AlSayed Y, Vanrhee F, Barlogie B (2013) Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 27(1):226–232. https://doi.org/10.1038/leu.2012.160

    Article  PubMed  CAS  Google Scholar 

  33. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD Jr, Barlogie B (2008) Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 140(6):625–634. https://doi.org/10.1111/j.1365-2141.2007.06921.x

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J, Barlogie B (2008) Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol 141(4):433–444. https://doi.org/10.1111/j.1365-2141.2008.06982.x

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Bene MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394(10192):29–38. https://doi.org/10.1016/S0140-6736(19)31240-1

    Article  PubMed  CAS  Google Scholar 

  36. Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M, Stevens D, Gunawardena S, Lutska Y, Qi K, Ukropec J, Qi M, Lin TS, Rifkin RM (2019) Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 185(3):492–502. https://doi.org/10.1111/bjh.15806

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Jakubowiak AJ, Chari A, Lonial S, Weiss BM, Comenzo RL, Wu K, Khokhar NZ, Wang J, Doshi P, Usmani SZ (2017) Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J Clin Oncol 35(15_suppl):8000. https://doi.org/10.1200/JCO.2017.35.15_suppl.8000

    Article  Google Scholar 

  38. Sonneveld P, Broijl A, Gay F, Boccadoro M, Einsele H, Blade J, Dimopoulos MA, Delforge M, Spencer A, Hajek R, Schjesvold F, Lonergan S, Smith E, Carson RL, Crist W, Garvin WS, Vermeulen J, Moreau P (2019) Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS). J Clin Oncol 37(15_suppl):TPS8055. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS8055

    Article  Google Scholar 

  39. Orlowski RZ, Goldschmidt H, Cavo M, Martin TG, Paux G, Oprea C, Facon T (2018) Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). J Clin Oncol 36(15_suppl):TPS8055. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS8055

    Article  Google Scholar 

  40. Easson EC, Russell MH (1963) Cure of Hodgkin's disease. Br Med J 1(5347):1704–1707. https://doi.org/10.1136/bmj.1.5347.1704

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, Hashmi SK, Marshall AL, Ashrani AA, Dispenzieri A, Kyle RA, Rajkumar SV, Go RS (2016) Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J 6(10):e486. https://doi.org/10.1038/bcj.2016.100

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV (2018) Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med 378(3):241–249. https://doi.org/10.1056/NEJMoa1709974

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Frei E 3rd, Gehan EA (1971) Definition of cure for Hodgkin's disease. Cancer Res 31(11):1828–1833

    PubMed  Google Scholar 

  44. Rajkumar SV (2008) Treatment of myeloma: cure vs control. Mayo Clin Proc 83(10):1142–1145. https://doi.org/10.4065/83.10.1142

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece

    Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Roussou, Nikolaos Kanellias, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Efstathios Kastritis & Meletios A. Dimopoulos

Authors
  1. Evangelos Terpos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ioannis Ntanasis-Stathopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Roussou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikolaos Kanellias
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Despina Fotiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Magdalini Migkou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Evangelos Eleutherakis-Papaiakovou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria Gavriatopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Efstathios Kastritis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Meletios A. Dimopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by INS, MR, NK, DF, MM, EEP, and MG. The first draft of the manuscript was written by INS and ET, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Evangelos Terpos.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Terpos, E., Ntanasis-Stathopoulos, I., Roussou, M. et al. Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. Ann Hematol 99, 1257–1264 (2020). https://doi.org/10.1007/s00277-020-04060-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04060-z

Keywords

Search

Navigation